Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198471 · ClinicalTrials.gov registry record · Phase 2
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00198471 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 10 participants.
The verdict
NCT00198471, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
Interventions
- DRUG Vitrase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198471
The ClinicalTrials.gov registry entry for NCT00198471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitrase is the first listed.
NCT00198471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198471 about?
NCT00198471 is a clinical study titled "Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment". The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
What is the current status of trial NCT00198471?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00198471?
The interventions under investigation include: Vitrase (DRUG).
Who is sponsoring clinical trial NCT00198471?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.